drugset / Trial / NCT04797013

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ

NCT04797013

RandomizedParallel-groupSingle-blindTreatment

Summary

A Phase Ⅲ, Multicenter, Prospective, Randomized, Open Label, Blinded-endpoint (PROBE) Controlled Trial of Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) for Injection Versus Alteplase for Acute Ischemic Stroke Within 4.5 Hours

Timeline

Start
2021-06-12
Primary completion
2022-05-29
Completion
2022-07-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alteplase Protein / enzyme biologic 0.9 mg/kg Intravenous
Comparator Tenecteplase Protein / enzyme biologic 0.25 mg/kg Intravenous

Indications